Pharmaceutical Printer of Inserts, Labels and More
Since 1928, we have been at the forefront of development in the pharmaceutical print industry. Beyond our reputation as the preeminent pharmaceutical printer, we now supply labeling and printing services for medical devices, as well as the bio-tech industry. We are committed to developing and then printing innovative materials that make it easier for you to get vital information to your customers. We do it all through a tried and tested foundation in Current Good Manufacturing Practices (CGMP) and ISO 9001:2014 standards that constantly work to achieve consistency in all of our print processes.
We are proud to boast that Pharmaceutic Litho is one of the few pharmaceutical printers with over 75,000 sq. ft. dedicated solely to pharmaceutical printing. Even so, we continue to grow and expand our secondary packaging services for the pharmaceutical and bio-tech industries in order to build on our reputation as the standard for quality and service in the pharma printing industries.
LATEST NEWS: Pharmaceutic Litho & Label Company Acquires Plymouth Printing
Wilton, CT — Pharmaceutic Litho & Label Company is excited to announce the acquisition of Plymouth Printing Company, Inc. As a current Good Manufacturing Practices (cGMP) compliant specialty printer that exclusively serves the pharmaceutical, biotech and medical device industries... continue reading
Pharmaceutical Printer Products
years in print
printed items each year
Pharmaceutical Printer News
Pharmaceutic Litho and Label (“PLLC”) is pleased to announce the acquisition of Plymouth Printing Company, Inc. (“Plymouth”). PLLC is a current Good Manufacturing Practices (cGMP) compliant specialty printer that exclusively serves theRead More…
Catalent, Inc., the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, announced an agreement for Catalent
GENEVA (AP) — Swiss pharmaceuticals company Novartis says a key measure of its profits fell 3 percent in the second quarter, largely because of new generic competition for its top cancer drug,Read More…